Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

NCT02261220 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.

NCT NCT02261220
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02261220 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors
Lead sponsor
MedImmune LLC
Phase
Phase 1
Overall status
Completed
Start date
October 13, 2014
Completion date
January 27, 2020
Enrollment
380 (actual)
Sites
75

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors